Precision Medicine in Oncology® | Specialty

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues

August 21st 2014

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Dr. Stuart on Risks of Phase I Liver Dysfunction Studies

August 14th 2014

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer

August 13th 2014

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Research Leader Looks Beyond Genetic Mechanisms of Acquired Resistance to TKI Therapies

August 12th 2014

Settlemen addressed broad questions about his research into acquired resistance mechanisms in an interview with OncologyLive.

Two-Part Series to Explore Use of Biomarkers in GU Cancer Treatment

August 12th 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

Dr. Gandara Discusses Third-Generation EGFR TKIs

August 11th 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

The Pivotal Role of Cooperative Group Trials

August 8th 2014

Managing Toxicities Associated With Regorafenib

August 8th 2014

Case Studies in Advanced Colorectal Cancer

August 8th 2014

Optimal Dosing of Regorafenib in CRC

August 8th 2014

Treatment Options for Advanced CRC

August 8th 2014

Attacking Acquired Mutations: Researchers Aim to Make Molecularly Targeted Cancer Therapies "Smarter"

August 8th 2014

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

PALB2, BRCA2 Gene Mutations Confer Similar Breast Cancer Risk

August 7th 2014

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene

Maintaining a Framework In Molecular Diagnostic Testing

August 6th 2014

Nobody disputes the need for careful, judicious diagnostic testing. But as the number of individual gene tests continues to grow, clinicians are struggling to keep up. On the one hand, using diagnostic markers like KRAS in colon cancer or hormone receptor status in breast cancer to select the most appropriate chemotherapy regimen is essential.

Evolving Therapeutic Landscape in Breast Cancer

August 5th 2014

Case Studies: Treating Metastatic Breast Cancer

August 5th 2014

Clinical Setting for Eribulin in Metastatic Breast Cancer

August 5th 2014

Treatment Strategies in ER-Positive Breast Cancer

August 5th 2014